TNF and inflammatory bowel disease: These results are consistent with the results of other studies comparing the real-world effectiveness and safety of vedolizumab and anti-TNFα for the treatment of IBD and may be related to the gut-selective mode of action of vedolizumab compared with the systemic immunosuppression of anti-TNFα [11–16, 24].